This content is in French.
SRC enzyme: a new target for anticancer antibodies
19 mars 2026
By Elodie Vaz | Published on March 19, 2026 | 3 min readFor over half a century, the oncogenic enzyme SRC has held a central place in cancer research. Identified in the 1970s as the first oncogene by J. Michael Bishop and Harold Varmus—a discovery awarded the Nobel Prize in 1989—this finding profoundly transformed the genetic understanding of cancer. SRC encodes an enzyme involved in intracellular
By Elodie Vaz | Published on March 19, 2026 | 3 min read
For over half a century, the oncogenic enzyme SRC has held a central place in cancer research. Identified in the 1970s as the first oncogene by J. Michael Bishop and Harold Varmus—a discovery awarded the Nobel Prize in 1989—this finding profoundly transformed the genetic understanding of cancer. SRC encodes an enzyme involved in intracellular signaling pathways that promote tumor proliferation.
For over half a century, the oncogenic enzyme SRC has held a central place in cancer research. Identified in the 1970s as the first oncogene by J. Michael Bishop and Harold Varmus—a discovery awarded the Nobel Prize in 1989—this finding profoundly transformed the genetic understanding of cancer. SRC encodes an enzyme involved in intracellular signaling pathways that promote tumor proliferation.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
View the source
